|
Tender Result Brief :
|
Contract awarded for Tetanus immunoglobulins and other active substances
{
"detected_language": "hungarian",
"translated_text": "lot-0001, title: afatinib, description: acquisition of an active ingredient subject to detailed accounting, aimed at concluding a framework agreement, within the framework of an open procedure according to section 105 (1) a) of the public procurement act, with the possibility of further extending the active period of the framework agreement. part 1: afatinib (oeno: 06022) basic quantity: 611,520 mg optional quantity: 305,760 mg minimum mandatory quantity of price discount to be provided for the basic quantity: 2,240 mg minimum mandatory quantity of price discount to be provided for the optional quantity: 1,120 mg in the procedure, the contracting authority intends to exercise the option under section 6 (1) of government decree 16/2012 (ii. 16.), thus the contracting authority stipulates the mandatory provision of price discounts exceeding the framework quantity, both for the basic and optional quantities (mandatory discount). in addition to the mandatory discount, bidders may also offer additional discounts at their discretion, the quantity of which must be specified in such a way that it is divisible by the smallest packaging unit of the given medicine, resulting in a positive integer. the contracting authority draws attention to the fact that the name, potency, packaging, and form of administration of the medicine (product, preparation) offered by the bidder is considered a detailed offer, thus it cannot be supplemented or modified! the offered medicine must have: - a marketing authorization in the public registry of the national public health and medical officer service on the day of the bid submission, and - must be validly listed in the pupha database containing the medicines accepted for social insurance (tb) support by the national health insurance fund manager on the day of the bid submission, and - the offered medicine must also be validly listed in the pupha database at the latest at the time of concluding the framework agreement (in detail: kd). the bidder must be listed in the registry of wholesalers on the day of the bid submission. the bidder must also have the marketing authorization for the product(s), thus if the bidder is not the holder of the marketing authorization, a declaration regarding the marketing authorization from the holder must also be submitted as part of the bid (in detail: kd). a valid bid submission further requires registration in the electronic detailed reporting system according to section 2/e (1) of nm decree 9/1993 (iv.2.) until the deadline for bid submission as described in the kd. condition for contract conclusion: the successful bidder must obtain successful qualification in the online reporting system as detailed in the kd. the electronic system can be found at: https:\\teteles.neak.gov.hu. detailed rules are contained in the kd. the warranty (expiry) period of the medicine is the time specified in the legislation or authority authorization. the winning bidder as the seller is obliged to ensure that the expiry date of the medicine extends for at least 12 months from the date of delivery, provided that if the expiry date of the medicine is less than 12 months at the time of delivery, the unused medicine within the expiry date must be exchanged for one with at least a 12-month expiry at least 1 month before the expiry date. in consideration of section 73 (1) j) of the public procurement act, the contracting authority draws attention to the fact that - a bid is invalid if it contains a total bid price higher than the net wholesale price calculated from the mg unit price of the lowest-priced medicine containing the given active ingredient listed in the pupha database on the day of the bid submission multiplied by the total framework quantity. lot-0002, title: rizankizumab, description: acquisition of an active ingredient subject to detailed accounting, aimed at concluding a framework agreement, within the framework of an open procedure according to section 105 (1) a) of the public procurement act, with the possibility of further extending the active period of the framework agreement. part 2: rizankizumab (oeno: 06083) basic quantity: 858,300 mg optional quantity: 429,150 mg minimum mandatory quantity of price discount to be provided for the basic quantity: 300 mg minimum mandatory quantity of price discount to be provided for the optional quantity: 100 mg in the procedure, the contracting authority intends to exercise the option under section 6 (1) of government decree 16/2012 (ii. 16.), thus the contracting authority stipulates the mandatory provision of price discounts exceeding the framework quantity, both for the basic and optional quantities (mandatory discount). in addition to the mandatory discount, bidders may also offer additional discounts at their discretion, the quantity of which must be specified in such a way that it is divisible by the smallest packaging unit of the given medicine, resulting in a positive integer. the contracting authority draws attention to the fact that the name, potency, packaging, and form of administration of the medicine (product, preparation) offered by the bidder is considered a detailed offer, thus it cannot be supplemented or modified! the offered medicine must have: - a marketing authorization in the public registry of the national public health and medical officer service on the day of the bid submission, and - must be validly listed in the pupha database containing the medicines accepted for social insurance (tb) support by the national health insurance fund manager on the day of the bid submission, and - the offered medicine must also be validly listed in the pupha database at the latest at the time of concluding the framework agreement (in detail: kd). the bidder must be listed in the registry of wholesalers on the day of the bid submission. the bidder must also have the marketing authorization for the product(s), thus if the bidder is not the holder of the marketing authorization, a declaration regarding
estimated value excluding vat: 6834000000.00 huf.Tetanus immunoglobulins and other active substances
|
